The Research Progress in Immunotherapy of Tuberculosis

Overview

Journal Front Cell Infect Microbiol

Specialties Cell Biology
Infectious Diseases
Microbiology

Date 2021 Dec 6

PMID 34869066

Citations 17

Authors

Jie Mi

Yan Liang

Jianqin Liang

Wenping Gong

Shuyong Wang

Junxian Zhang

Zhiming Li

Xueqiong Wu

Affiliations

Soon will be listed here.

Abstract

Tuberculosis (TB) is a serious public health problem worldwide. The combination of various anti-TB drugs is mainly used to treat TB in clinical practice. Despite the availability of effective antibiotics, effective treatment regimens still require long-term use of multiple drugs, leading to toxicity, low patient compliance, and the development of drug resistance. It has been confirmed that immune recognition, immune response, and immune regulation of () determine the occurrence, development, and outcome of diseases after infection. The research and development of TB-specific immunotherapy agents can effectively regulate the anti-TB immune response and provide a new approach toward the combined treatment of TB, thereby preventing and intervening in populations at high risk of TB infection. These immunotherapy agents will promote satisfactory progress in anti-TB treatment, achieving the goal of "ultra-short course chemotherapy." This review highlights the research progress in immunotherapy of TB, including immunoreactive substances, tuberculosis therapeutic vaccines, chemical agents, and cellular therapy.

Citing Articles

Cell therapies for viral diseases: a new frontier.

Nardo D, Maddox E, Riley J Semin Immunopathol. 2025; 47(1):5.

PMID: 39747475 PMC: 11695571. DOI: 10.1007/s00281-024-01031-8.

Enhanced Immune Responses Against Through Heat-Killed BCG with Squalene-in-water Emulsion Adjuvant.

Zhu C, Song Q, Li X, He X, Li J Indian J Microbiol. 2024; 64(4):1929-1937.

PMID: 39678980 PMC: 11645453. DOI: 10.1007/s12088-024-01278-7.

Distinguish active tuberculosis with an immune-related signature and molecule subtypes: a multi-cohort analysis.

Shan Q, Li Y, Yuan K, Yang X, Yang L, He J Sci Rep. 2024; 14(1):29564.

PMID: 39609541 PMC: 11605007. DOI: 10.1038/s41598-024-80072-3.

IFNγ-secreting T cells that highly express IL-2 potently inhibit the growth of intracellular in macrophages.

Zhu L, Wang B, Gu J, Zhou J, Wu Y, Xu W Front Immunol. 2024; 15:1469118.

PMID: 39575242 PMC: 11578947. DOI: 10.3389/fimmu.2024.1469118.

The progress of drug targets.

Zhang X, Zhao R, Qi Y, Yan X, Qi G, Peng Q Front Med (Lausanne). 2024; 11:1455715.

PMID: 39497852 PMC: 11533868. DOI: 10.3389/fmed.2024.1455715.

References

Deng J, Yang Y, He J, Xie Z, Luo F, Xu J . Vitamin D receptor activated by vitamin D administration alleviates Mycobacterium tuberculosis-induced bone destruction by inhibiting NFκB-mediated aberrant osteoclastogenesis. FASEB J. 2021; 35(6):e21543. DOI: 10.1096/fj.202100135R. View

Denis M, Gregg E, Ghandirian E . Cytokine modulation of Mycobacterium tuberculosis growth in human macrophages. Int J Immunopharmacol. 1990; 12(7):721-7. DOI: 10.1016/0192-0561(90)90034-k. View

Lu J, Chen B, Wang G, Fu L, Shen X, Su C . Recombinant tuberculosis vaccine AEC/BC02 induces antigen-specific cellular responses in mice and protects guinea pigs in a model of latent infection. J Microbiol Immunol Infect. 2014; 48(6):597-603. DOI: 10.1016/j.jmii.2014.03.005. View

Fehlbaum P, Rao M, Zasloff M, Anderson G . An essential amino acid induces epithelial beta -defensin expression. Proc Natl Acad Sci U S A. 2000; 97(23):12723-8. PMC: 18831. DOI: 10.1073/pnas.220424597. View

Huang C, Hsieh W . Efficacy of Mycobacterium vaccae immunotherapy for patients with tuberculosis: A systematic review and meta-analysis. Hum Vaccin Immunother. 2017; 13(9):1960-1971. PMC: 5612516. DOI: 10.1080/21645515.2017.1335374. View

Francisco-Cruz A, Mata-Espinosa D, Ramos-Espinosa O, Marquina-Castillo B, Estrada-Parra S, Xing Z . Efficacy of gene-therapy based on adenovirus encoding granulocyte-macrophage colony-stimulating factor in drug-sensitive and drug-resistant experimental pulmonary tuberculosis. Tuberculosis (Edinb). 2016; 100:5-14. DOI: 10.1016/j.tube.2016.05.015. View

Singh A, Mohan A, Dey A, Mitra D . Inhibiting the programmed death 1 pathway rescues Mycobacterium tuberculosis-specific interferon γ-producing T cells from apoptosis in patients with pulmonary tuberculosis. J Infect Dis. 2013; 208(4):603-15. DOI: 10.1093/infdis/jit206. View

Liang Y, Zhang X, Xiao L, Bai X, Wang X, Yang Y . Immunogenicity and therapeutic effects of pVAX1- rv1419 DNA from Mycobacterium tuberculosis. Curr Gene Ther. 2016; . View

Mayosi B, Ntsekhe M, Bosch J, Pandie S, Jung H, Gumedze F . Prednisolone and Mycobacterium indicus pranii in tuberculous pericarditis. N Engl J Med. 2014; 371(12):1121-30. PMC: 4912834. DOI: 10.1056/NEJMoa1407380. View

10.

Gong W, Liang Y, Mi J, Xue Y, Wang J, Wang L . A peptide-based vaccine ACP derived from antigens of Mycobacterium tuberculosis induced Th1 response but failed to enhance the protective efficacy of BCG in mice. Indian J Tuberc. 2022; 69(4):482-495. DOI: 10.1016/j.ijtb.2021.08.016. View

11.

Hoagland D, Liu J, Lee R, Lee R . New agents for the treatment of drug-resistant Mycobacterium tuberculosis. Adv Drug Deliv Rev. 2016; 102:55-72. PMC: 4903924. DOI: 10.1016/j.addr.2016.04.026. View

12.

Erokhin V, Vasileva I, Konopliannikov A, Chukanov V, Tsyb A, Bagdasarian T . [Systemic transplantation of autologous mesenchymal stem cells of the bone marrow in the treatment of patients with multidrug-resistant pulmonary tuberculosis]. Probl Tuberk Bolezn Legk. 2008; (10):3-6. View

13.

Patil P, Cheng T, Zulueta M, Yang S, Lico L, Hung S . Total synthesis of tetraacylated phosphatidylinositol hexamannoside and evaluation of its immunomodulatory activity. Nat Commun. 2015; 6:7239. PMC: 4468851. DOI: 10.1038/ncomms8239. View

14.

Ramos-Espinosa O, Islas-Weinstein L, Peralta-Alvarez M, Lopez-Torres M, Hernandez-Pando R . The use of immunotherapy for the treatment of tuberculosis. Expert Rev Respir Med. 2018; 12(5):427-440. DOI: 10.1080/17476348.2018.1457439. View

15.

Rodriguez A, Tjarnlund A, Ivanji J, Singh M, Garcia I, Williams A . Role of IgA in the defense against respiratory infections IgA deficient mice exhibited increased susceptibility to intranasal infection with Mycobacterium bovis BCG. Vaccine. 2005; 23(20):2565-72. DOI: 10.1016/j.vaccine.2004.11.032. View

16.

Yuan X, Wen Q, Ni M, Wang L . Immune formulation-assisted conventional therapy on anti-infective effectiveness of multidrug-resistant Mycobacterium tuberculosis infection mice. Asian Pac J Trop Med. 2016; 9(3):293-7. DOI: 10.1016/j.apjtm.2016.01.031. View

17.

Sia J, Georgieva M, Rengarajan J . Innate Immune Defenses in Human Tuberculosis: An Overview of the Interactions between Mycobacterium tuberculosis and Innate Immune Cells. J Immunol Res. 2015; 2015:747543. PMC: 4516846. DOI: 10.1155/2015/747543. View

18.

Sharma S, Katoch K, Sarin R, Balambal R, Jain N, Patel N . Efficacy and Safety of Mycobacterium indicus pranii as an adjunct therapy in Category II pulmonary tuberculosis in a randomized trial. Sci Rep. 2017; 7(1):3354. PMC: 5469738. DOI: 10.1038/s41598-017-03514-1. View

19.

Dwivedi V, Bhattacharya D, Singh M, Bhaskar A, Kumar S, Fatima S . Allicin enhances antimicrobial activity of macrophages during Mycobacterium tuberculosis infection. J Ethnopharmacol. 2018; 243:111634. DOI: 10.1016/j.jep.2018.12.008. View

20.

Gong W, Liang Y, Wu X . The current status, challenges, and future developments of new tuberculosis vaccines. Hum Vaccin Immunother. 2018; 14(7):1697-1716. PMC: 6067889. DOI: 10.1080/21645515.2018.1458806. View